Logo

Synthetic Genetics Company Codon Closes $20M in Series B VC Round

Dec 19, 2006
NEW YORK (GenomeWeb News) — Synthetic genetics company Codon Devices has pocketed $20 million in a Series B round of venture capital financing, Codon said today.
 
Codon CEO John Danner said the company will use the cash to develop its BioFAB production platform, which uses informatics, robotics, and sequencing technology to synthesize gene codes.
 
In July Codon reported it had built a 35-kilobase gene cluster for the pharmaceutical company Microbia.

 

The company also plans use the money to expand its protein and metabolic engineering and will push ahead with a global sales agenda.
 
Highland Capital Partners led the round. Contributors included Alloy Ventures, Flagship Ventures, Khosla Ventures and Kleiner Perkins Caufield & Byers.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.